SCHEMBL7677930

SCHEMBL7677930

Cc1c2c(n(C)c1C(=O)c1ccc(C#N)cc1)CC(=O)O2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
PKM P14618 1/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA12 O43570 1/20 0.34
CA9 Q16790 1/20 0.34
GAA P10253 2/20 0.33
SLC6A3 Q01959 1/20 0.32
GSK3B P49841 2/20 0.32
MAPT P10636 2/20 0.32
CD274 Q9NZQ7 1/20 0.32
GFER P55789 1/20 0.32
HTR1A P08908 1/20 0.31
DRD2 P14416 1/20 0.31
HTR2A P28223 1/20 0.31
SLC6A4 P31645 1/20 0.31
HTR7 P34969 1/20 0.31
HRH1 P35367 1/20 0.31
DRD3 P35462 1/20 0.31
HTR2B P41595 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8048118 0.87 PTGS2 (0.51) ALDH1A1
SCHEMBL7674831 0.84 NPC1 (0.38) ALDH1A1MAPTHTR1AHTR2AHRH1
SCHEMBL7674670 0.84 ABCB11 (0.41) ALDH1A1MAPT
SCHEMBL7678111 0.81 SRD5A2 (0.38) GAAMAPT
SCHEMBL7678461 0.77 TSHR (0.47) ALDH1A1PKMCA1CA2CA12
SCHEMBL7674520 0.76 ALDH1A1 (0.37) ALDH1A1PKMCA1CA2CA12
SCHEMBL7680879 0.75 ALDH1A1 (0.35) ALDH1A1PKMCA1CA2SLC6A3
SCHEMBL7681373 0.71 ALDH1A1 (0.34) ALDH1A1CA1CA2CA12CA9
SCHEMBL7678566 0.69 HTT (0.40) ALDH1A1MAPT
SCHEMBL7674713 0.69 GRM2 (0.39) ALDH1A1CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885PKM 4613/4885CA1 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.